AstraZeneca · 1 day ago
NF1-PN Patient Marketing Intern (Undergraduate)
AstraZeneca is seeking undergraduate students for a 10-week Patient Marketing Internship at their Alexion Rare Disease site in Boston, MA. The role involves creating social media content, identifying gaps in patient engagement, and optimizing community education resources.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Work with agency partner to create social media posts in alignment with brand strategy
Work with Patient Marketing lead to identify gaps in patient & caregiver engagement and propose additional new resources to address those needs
Work with field PEM (patient education manager team) to identify additional opportunities for community engagement and education and optimize our current tactical plan to enhance those critical resources
Qualification
Required
Sophomore and Junior students majoring in Business Administration, Marketing, or a related field
Candidates must have an expected graduation date after August 2026
Social media knowledge with key customer platforms (Facebook, X, TikTok, YouTube, Reddit)
MS Office Proficiency
Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design
US Work Authorization is required at time of application
Ability to report onsite to the Seaport neighborhood in Boston, MA 3 days per week
Benefits
Short-term incentive bonus opportunity
Equity-based long-term incentive program (salaried roles)
Retirement contribution (hourly roles)
Commission payment eligibility (sales roles)
Qualified retirement program [401(k) plan]
Paid vacation and holidays
Paid leaves
Health benefits including medical, prescription drug, dental, and vision coverage
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Recent News
2026-01-09
2026-01-09
2026-01-09
Company data provided by crunchbase